Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins

Blood

Volumn 124, Issue 2, 2014, Pages 167-175

  Jauréguiberry, Stéphane ^a,b   Ndour, Papa A ^b   Roussel, Camille ^b   Ader, Flavie ^a   Safeukui, Innocent ^c   Nguyen, Marie ^d   Biligui, Sylvestre ^b   Ciceron, Liliane ^b   Mouri, Oussama ^b   Kendjo, Eric ^a,b   Bricaire, François ^a   Vray, Muriel ^d   Angoulvant, Adéla ^e   Mayaux, Julien ^a   Haldar, Kasturi ^c   Mazier, Dominique ^a,b   Danis, Martin ^a,b   Caumes, Eric ^a   Thellier, Marc ^a,b   Buffet, Pierre ^a,b,f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b France   (France)

^c UNIVERSITY OF NOTRE DAME   (United States)

^d INSTITUT PASTEUR   (France)

^e BICÊTRE HOSPITAL   (France)

^f Laboratory of Excellence GR Ex   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; ARTESUNATE; QUININE;

ADULT; ANEMIA; ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HEMOLYSIS; DISEASE SEVERITY; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE KINETICS; ERYTHROCYTE LIFESPAN; ERYTHROCYTE STRUCTURE; ERYTHROCYTE VOLUME; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; MALARIA; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRAVEL;

ADULT; ANEMIA, HEMOLYTIC; ANTIMALARIALS; ARTEMISININS; ERYTHROCYTES; FEMALE; FOLLOW-UP STUDIES; HEMOLYSIS; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904121729     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-555953     Document Type: Article

References (40)

1. WHO. The treatment of malaria, 2nd ed. Geneva, Switzerland: WHO Press, 2010
2. Dondorp AM, Fanello CI, Hendriksen IC, et al; AQUAMAT group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647-1657.
3. Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366(9487):717-725.
4. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.
5. Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013;12:241.
6. Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011;17(5):771-777.
7. Briggs M, Arguin PM; Centers for Disease Control and Prevention (CDC). Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria - worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013;62(1):5-8.
8. Caramello P, Balbiano R, De Blasi T, Chiriotto M, Deagostini M, Calleri G. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother. 2012;67(8):2053-2054.
9. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012;11(1):102.
10. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard GD, Cramer JP. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J. 2012;11(1):169.
11. Kano S. Artemisinin-based combination therapies and their introduction in Japan. J Infect Chemother. 2010;16(6):375-382.
12. MMV. Experts Group Meeting on delayed anaemia following treatment with injectable artesunate. Wien, Austria: 2013. http://www.mmv.org/sites/default/ files/uploads/docs/events/2013/InjectableArtesunateExpertGroupMeeting.pdf.
13. World Health Organization Global Malaria Program. WHO Information Note on Delayed Haemolytic Anaemia following Treatment with Artesunate. WHO Note. 2013;(October):1-2.
14. Finaurini S, Basilico N, Corbett Y, et al. Dihydroartemisinin inhibits the human erythroid cell differentiation by altering the cell cycle. Toxicology. 2012;300(1-2):57-66.
15. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90(5):2037-2040. (Pubitemid 27377317)
16. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002;18(10):458-464.
17. Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000;182(2):629-633. (Pubitemid 30651065)
18. Newton PN, Chotivanich K, Chierakul W, et al. A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes. Blood. 2001;98(2):450-457.
19. Buffet PA, Milon G, Brousse V, et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood. 2006;107(9):3745-3752.
20. Buffet PA, Safeukui I, Deplaine G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood. 2011;117(2):381-392.
21. ANSM-CNR La Pitié-Salpêtrière. Protocole d'utilisation thérapeutique et de receuil d'informations. Malacef (artésunate) 60 mg, poudre et solvant pour solution injectable. Laboratoire ACE Pharmaceuticals BV // ARTECEF BV. Available at: http://ansm.sante.fr/var/ansm-site/storage/original/application/ 01d138a64031bcf9f37fa2737308caa5.pdf. Accessed December 2011.
22. WHO. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94(suppl):1-90.
23. Société de Pathologie Infectieuse de Langue Française. Recommendations for clinical practice. Management and prevention of imported Plasmodium falciparum malaria. (Revision 2007 of the 1999 Consensus conference). Short text [in English, French]. Med Mal Infect. 2008;38(2):54-67, 39-53.
24. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872):81-84.
25. Haut Conseil de al Santé Publique. Place de l'artésunate injectable dans le traitement du paludisme grave chez l'adulte et l'enfant. Available at: http://www.hcsp.fr/explore.cgi/telecharger/hcspr20130201- palugraveartesunate.pdf. 2013 Accessed February 1, 2013.
26. Safeukui I, Correas JM, Brousse V, et al. Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood. 2008;112(6):2520-2528.
27. Safeukui I, Buffet PA, Deplaine G, et al. Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen. Blood. 2012;120(2):424-430.
28. Safeukui I, Buffet PA, Perrot S, et al. Surface area loss and increased sphericity account for the splenic entrapment of subpopulations of Plasmodium falciparum ring-infected erythrocytes. PLoS ONE. 2013;8(3):e60150.
29. Douglas NM, Anstey NM, Buffet PA, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135.
30. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008;48(6):1231-1238. (Pubitemid 351793504)
31. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9):1785-1792.
32. Rolling T, Agbenyega T, Issifou S, et al. Delayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malaria - A Double-center Prospective Study [published online ahead of print January 29, 2014]. J Infect Dis.
33. Deplaine G, Safeukui I, Jeddi F, et al. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood. 2011;117(8):e88-e95.
34. White NJ, Chapman D, Watt G. The effects of multiplication and synchronicity on the vascular distribution of parasites in falciparum malaria. Trans R Soc Trop Med Hyg. 1992;86(6):590-597. (Pubitemid 23012896)
35. Price RN, Simpson JA, Nosten F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg. 2001;65(5):614-622. (Pubitemid 33134602)
36. Olliaro P, Djimdé A, Dorsey G, et al. Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Am J Trop Med Hyg. 2011;85(4):619-625.
37. Looareesuwan S, Davis TM, Pukrittayakamee S, et al. Erythrocyte survival in severe falciparum malaria. Acta Trop. 1991;48(4):263-270.
38. Biemba G, Gordeuk VR, Thuma PE, Mabeza GF, Weiss G. Prolonged macrophage activation and persistent anaemia in children with complicated malaria. Trop Med Int Health. 1998;3(1):60-65. (Pubitemid 28081022)
39. Metha SR, Joshi V, Lazar AI. Unusual acute and chronic complications of malaria. J Assoc Physicians India. 1996;44(7):451-453. (Pubitemid 126459192)
40. Perkins S. Diagnosis of anemia. In: Kjeldsberg C, Perkins S, eds. Practical Diagnosis of Hematologic Disorders, 5th Edition. Chicago, IL: American Society of Clinical Pathology Press; 2010.